by TractManager | Sep 16, 2021 | Emerging Technology Report
Lecanemab (formerly, BAN2401) is an investigational, intravenously administered anti-amyloid beta (Aβ) protofibril antibody proposed for the treatment of early Alzheimer disease.If you have a Hayes login, click here to view the full report on the Knowledge...
by TractManager | Sep 10, 2021 | Molecular Test Assessment
This report evaluates the analytical validity, clinical validity, and clinical utility of the GeneSight Psychotropic (Myriad Neuroscience) test.If you have a Hayes login, click here to view the full report on the Knowledge Center.
by TractManager | Sep 9, 2021 | Emerging Technology Report
Kerendia (finerenone) is a nonsteroidal mineralocorticoid receptor antagonist indicated to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and...
by TractManager | Sep 9, 2021 | Emerging Technology Report
The OCS Heart is a portable extracorporeal heart perfusion and monitoring system indicated for the preservation of donor-after-brain-death (DBD) donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of prolonged...
by TractManager | Sep 1, 2021 | News
The Food and Drug Administration (FDA) is requiring new and updated warnings for Janus kinase (JAK) inhibitors Xeljanz/Xeljanz XR (tofacitinib; Pfizer), Olumiant (baricitinib; Eli Lilly and Co.), and Rinvoq (upadacitinib; AbbVie Inc).The FDA completed a review of a...
Recent Comments